港交所(00388.HK)欧冠升:持续研究推出18A章相关ETF及结构性产品
港交所(00388.HK)集团行政总裁欧冠升指出,自2018年起已有超过100家生科企在香港主板上市,集资逾2,600亿元,2020年互联互通扩容,符合条件的未盈利生物科技公司获纳入合资格投资标的,以及近年来推出ETF、期货及期权等投资产品亦为生物科技板块带来支持。
他表示,生物科技股已成为香港市场重要一环,现时有效上市申请中有近40家为相关企业,分析预期全球生物科技市场规模将由2020年的7,530亿美元,增长至2030年的1.7万亿美元,交易所将致力提升市场流动性,促进资本活力,以支持中小市值公司发展,包括持续研究推出与18A章相关的ETF及结构性产品,以满足投资者需求。
启明创投主管合伙人梁(颖)宇透露,市场波动影响,上半年生物科技相关的私人市场融资金额有所下降,但宗数却上升,反映投资者转向投资更多更早期研发项目,该行60%投资公司过去一年均有获得融资,有信心当IPO窗口恢复后,会有不少优质企业排队上市。
港交所主席史美伦表示,环境、社会和管治(ESG)已成为全球共同目标,各国正携手面对气候变化、食品安全、人口老龄化及新兴传染病等问题,疫情加速医疗健康行业变革,数字医疗产业、健康数据一体化、居家治疗等成为新常态,均正改变人类的未来发展,而亚太区特别是中国更是新兴产业先行者,相信香港可担任资本、技术及人才的枢纽。
她指出,港交所推行上市改革,让未盈利生物科技企业接触到国际资本,港府亦已承诺提供100亿元支持产业长期商业化发展,交易所未来将与持份者及监管机构持续探讨优化市场架构。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.